Drug Profile
YSA 2021
Alternative Names: YSA2021Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Yungjin Pharm Co
- Class Bacterial vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in South Korea (unspecified route) (Yungjin pharmaceuticals pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in South Korea
- 21 Jan 2016 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in South Korea (unspecified route) prior to January 2016 (Yungjin Pharm's pipeline, January 2016)